KR20010101992A - 마취의 조정 - Google Patents

마취의 조정 Download PDF

Info

Publication number
KR20010101992A
KR20010101992A KR1020017009855A KR20017009855A KR20010101992A KR 20010101992 A KR20010101992 A KR 20010101992A KR 1020017009855 A KR1020017009855 A KR 1020017009855A KR 20017009855 A KR20017009855 A KR 20017009855A KR 20010101992 A KR20010101992 A KR 20010101992A
Authority
KR
South Korea
Prior art keywords
dsip
anesthesia
activity
compound
anesthetic
Prior art date
Application number
KR1020017009855A
Other languages
English (en)
Korean (ko)
Inventor
크리스토버 존 더글라스 폼프레트
마이클 알키레
리챠드 에어
짐 휄론
Original Assignee
에스.엠.리틀우드
빅토리아유니버시티오브맨체스터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9902469.7A external-priority patent/GB9902469D0/en
Application filed by 에스.엠.리틀우드, 빅토리아유니버시티오브맨체스터 filed Critical 에스.엠.리틀우드
Publication of KR20010101992A publication Critical patent/KR20010101992A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020017009855A 1999-02-05 2000-02-01 마취의 조정 KR20010101992A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB9902469.7 1999-02-05
GBGB9902469.7A GB9902469D0 (en) 1999-02-05 1999-02-05 Brain metabolism
US12032699P 1999-02-17 1999-02-17
US60/120,326 1999-02-17
US15566199P 1999-09-24 1999-09-24
US60/155,661 1999-09-24
PCT/GB2000/000281 WO2000045832A2 (en) 1999-02-05 2000-02-01 Regulation of anaesthesia

Publications (1)

Publication Number Publication Date
KR20010101992A true KR20010101992A (ko) 2001-11-15

Family

ID=27269636

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017009855A KR20010101992A (ko) 1999-02-05 2000-02-01 마취의 조정

Country Status (15)

Country Link
EP (1) EP1148887A2 (id)
JP (1) JP2002536337A (id)
KR (1) KR20010101992A (id)
CN (1) CN1346278A (id)
AP (1) AP2001002245A0 (id)
AU (1) AU2445900A (id)
BR (1) BR0008046A (id)
CA (1) CA2360124A1 (id)
ID (1) ID30518A (id)
IL (1) IL144572A0 (id)
MX (1) MXPA01007949A (id)
NO (1) NO20013795D0 (id)
OA (1) OA11758A (id)
TR (1) TR200102265T2 (id)
WO (1) WO2000045832A2 (id)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1275308A1 (en) * 2001-07-13 2003-01-15 The Procter & Gamble Company Food composition offering stress relaxation to mammals
US20100210540A1 (en) * 2007-09-11 2010-08-19 Dorian Bevec Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
GB201116271D0 (en) * 2011-09-21 2011-11-02 Univ Cardiff Dispersion anaesthetic device
CN108376559B (zh) * 2018-02-28 2020-10-16 复旦大学附属中山医院 乙醛脱氢酶2基因型在麻醉剂量计算中的应用
CN112535727A (zh) * 2020-12-24 2021-03-23 安域生物制药(杭州)有限公司 一种具有睡眠改善作用的短肽凝胶及其制备方法
CN112908454B (zh) * 2021-02-26 2023-08-29 西安交通大学口腔医院 一种智能保管麻醉剂的方法及系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH634331A5 (de) * 1977-06-30 1983-01-31 Hoffmann La Roche Phosphorylierte nonapeptide und verfahren zu deren herstellung.
CA1188989A (en) * 1981-05-21 1985-06-18 Richard R. Scherschlicht Nonapeptide for the treatment of drug withdrawal symptoms
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
RU2104717C1 (ru) * 1995-07-07 1998-02-20 Новокузнецкий государственный институт усовершенствования врачей Способ анестезии при операциях у больных с синдромом лериша

Also Published As

Publication number Publication date
ID30518A (id) 2001-12-13
IL144572A0 (en) 2002-05-23
WO2000045832A2 (en) 2000-08-10
MXPA01007949A (es) 2003-06-04
AU2445900A (en) 2000-08-25
WO2000045832A3 (en) 2000-11-30
OA11758A (en) 2005-07-19
NO20013795L (no) 2001-08-02
EP1148887A2 (en) 2001-10-31
CA2360124A1 (en) 2000-08-10
AP2001002245A0 (en) 2001-09-30
JP2002536337A (ja) 2002-10-29
BR0008046A (pt) 2001-11-06
CN1346278A (zh) 2002-04-24
TR200102265T2 (tr) 2001-12-21
NO20013795D0 (no) 2001-08-02

Similar Documents

Publication Publication Date Title
Muir III et al. Effects of morphine, lidocaine, ketamine, and morphine-lidocaine-ketamine drug combination on minimum alveolar concentration in dogs anesthetized with isoflurane
Mann et al. The initiation of gait.
Valverde et al. Effect of lidocaine on the minimum alveolar concentration of isoflurane in dogs
Lee et al. Afferent properties and reflex functions of bronchopulmonary C-fibers
Thomas et al. Epidural dexamethasone reduces postoperative pain and analgesic requirements
US20120101073A1 (en) Novel Method For Treating Breathing Disorders or Diseases
US6562855B1 (en) Anaesthetic formulation comprising an NMDA-antagoinst and an alpha-2 adrenergic agonist
Seddighi et al. The effect of midazolam on the end-tidal concentration of isoflurane necessary to prevent movement in dogs
BG105889A (bg) Използване на ксенон за лечение на невроинтоксикации
WO2002089794A1 (en) Method for treating neuropathic pain and pharmaceutical preparation therefor
Fukui et al. Interaction between maropitant and carprofen on sparing of the minimum alveolar concentration for blunting adrenergic response (MAC-BAR) of sevoflurane in dogs
Greer et al. Ampakine therapy to counter fentanyl-induced respiratory depression
KR20010101992A (ko) 마취의 조정
US20230145940A1 (en) Neurotoxin compositions for use in treating cardiovascular disorders
Park et al. Efficacy of D-CPPene, a competitive N-methyl-D-aspartate antagonist in focal cerebral ischemia in the rat
Potts et al. Does angiotensin II have a significant tonic action on cardiovascular neurons in the rostral and caudal VLM?
De Villiers et al. Second-degree atrioventricular heart block after doxapram administration
Vass et al. Nitric oxide mediates capsaicin-induced increase in cochlear blood flow
Miyazato et al. Midlatency auditory-evoked potentials in the rat: effects of interventions that modulate arousal
BRPI0616144A2 (pt) composiÇço terapÊutica, uso de uma composiÇço terapÊutica,composiÇço farmacÊutica, e, uma primeira composiÇço terapÊutica compreendendo um composto s-nitrosotiol e uma segunda composiÇço terapÊutica compreendendo um segundo composto que nço o composto s-nitrosotiol
JPH11515015A (ja) 睡眠無呼吸の抑止方法
Rigotti et al. Anaesthesia for paediatric and geriatric patients
Karwacki et al. THE INFLUENCE OF SEVOFLURANE ON THE REACTIVITY
Nimmo et al. Effect of anaesthesia and surgery on pharmacokinetics and pharmacodvamics
Brosnan et al. Effects of trazodone and dexmedetomidine on fentanyl-mediated reduction of isoflurane minimum alveolar concentration in cats

Legal Events

Date Code Title Description
SUBM Surrender of laid-open application requested